This includes clinical trials targeting HER2 such as a phase II multi-institutional trial in ovarian cancer in which trastuzumab (Herceptin) was used as a single agent in patients determined HER2 positive by IHC [101]. The gene discussed is ERBB2; the disease is ovarian cancer.